WebDec 10, 2024 · Novel KIF18A Inhibitors for Treating Cancer December 2024 ACS Medicinal Chemistry Letters11(12):2368-2369 DOI:10.1021/acsmedchemlett.0c00592 Authors: Ram … WebApr 12, 2024 · Osimertinib is a third-generation epidermal growth factor receptor and tyrosine kinase inhibitor (EGFR-TKI) approved for the treatment of lung adenocarcinoma patients harboring EGFR mutations. However, acquired resistance to this targeted therapy is inevitable, leading to disease relapse within a few years. Therefore, understanding the …
Novel cancer therapies: treatments driven by tumour biology
WebOct 21, 2024 · The reliance of tumor cells on aerobic glycolysis is one of the emerging hallmarks of cancer. Pyruvate kinase M2 (PKM2), an important enzyme of glycolytic pathway, is highly expressed in a number of cancer cells. Tumor cells heavily depend on PKM2 to fulfill their divergent energetic and biosynthetic requirements, suggesting it as … WebMay 10, 2024 · Based on the finding that: among CDK1-TFCP2L1 pathway targets associated with urothelial differentiation in bladder cancer cells, ID2 is a factor significantly correlating with the tumor grade of bladder cancer; an ID2 activator exhibits a therapeutic effect on bladder cancer; and the combined administration of CDK1 inhibitor and ID2 … nova residence twin falls
Discovery of a Novel Bloom’s Syndrome Protein (BLM) Inhibitor ...
WebFeb 20, 2015 · Using BTB-1, the first identified Kif18A inhibitor, as a lead compound, we synthesized a collection of derivatives. We demonstrate that some of the synthesized derivatives potently inhibited the ATPase activity of Kif18A with a half maximal inhibitory concentration (IC50) value in the low micromolar range. WebSep 4, 2024 · KIF18A is overexpressed in various types of cancers, including but not limited to colon, breast, lung, pancreas, prostate, bladder, head, neck, cervix, and ovarian cancers. … WebNov 19, 2024 · Europe PMC is an archive of life sciences journal literature. nova richland wa